highly significantP < 0.001
In contrast, stage II–IV patients displayed persistent, highly significant OS benefits (all P < 0.001), consistent with a systematic review from the Cancer Care Ontario Program [ 24 ].
In contrast, stage II–IV patients displayed persistent, highly significant OS benefits (all P < 0.001), consistent with a systematic review from the Cancer Care Ontario Program [ 24 ].